Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Human Cancer Biology

Clinical
Cancer
Research

The Activation of the WNT Signaling Pathway Is a Hallmark in
Neuroï¬bromatosis Type 1 Tumorigenesis

Armelle Luscan1,4, Ghjuvan'Ghjacumu Shackleford5, Julien Masliah-Planchon1, Ingrid Laurendeau1,
Nicolas Ortonne10, Jennifer Varin1, FranÂ¸cois Lallemand14, Karen Leroy11, Valerie Dumaine6, Mikael Hivelin2,12,
Didier Borderie7, Thomas De Raedt15, Laurence Valeyrie-Allanore13, Frederique Larousserie8, Beno^t Terris3,9,
Laurent Lantieri2, Michel Vidaud1,4, Dominique Vidaud1,4, Pierre Wolkenstein13, Beatrice Parfait1,4,
Ivan Bieche1,14, Charbel Massaad5, and Eric Pasmant1,4

Abstract

Purpose: The hallmark of neuroï¬bromatosis type 1 (NF1) is the onset of dermal or plexiform
neuroï¬bromas, mainly composed of Schwann cells. Plexiform neuroï¬bromas can transform into malignant
peripheral nerve sheath tumors (MPNST) that are resistant to therapies.

Experimental Design: The aim of this study was to identify an additional pathway in the NF1
tumorigenesis. We focused our work on Wnt signaling that is highly implicated in cancer, mainly in
regulating the proliferation of cancer stem cells. We quantiï¬ed mRNAs of 89 Wnt pathway genes in 57 NF1-
associated tumors including dermal and plexiform neuroï¬bromas and MPNSTs. Expression of two major
stem cell marker genes and ï¬ve major epithelialâ€“mesenchymal transition marker genes was also assessed.
The expression of signiï¬cantly deregulated Wnt genes was then studied in normal human Schwann cells,
ï¬broblasts, endothelial cells, and mast cells and in seven MPNST cell lines.

Results: The expression of nine Wnt genes was signiï¬cantly deregulated in plexiform neuroï¬bromas in
comparison with dermal neuroï¬bromas. Twenty Wnt genes showed altered expression in MPNST biopsies
and cell lines. Immunohistochemical studies conï¬rmed the Wnt pathway activation in NF1-associated
MPNSTs. We then conï¬rmed that the knockdown of NF1 in Schwann cells but not in epithelial cells
provoked the activation of Wnt pathway by functional transfection assays. Furthermore, we showed that the
protein expression of active b-catenin was increased in NF1-silenced cell lines. Wnt pathway activation was
strongly associated to both cancer stem cell reservoir and Schwannâ€“mesenchymal transition.

Conclusion: We highlighted the implication of Wnt pathway in NF1-associated tumorigenesis. Clin

Cancer Res; 20(2); 358â€“71. Ã“2013 AACR.

Introduction

Neuroï¬bromatosis type 1 (NF1) is an autosomal dom-
inant neurocutaneous disorder affecting 1 in 3,000
individuals worldwide (1). The NF1 gene is located in the
chromosome region 17q11.2. Its protein product, neuroï¬-
bromin, functions as a negative regulator of RAS proteins.

The main clinical features of NF1 are cafe-au-lait macules,
skinfold freckling, iris Lisch nodules, as well as skeletal
and cardiovascular abnormalities. NF1 patients have an
increased risk of both benign and malignant tumors, there-
fore, NF1 is classiï¬ed as a tumor predisposition syndrome.
The most common tumors are benign peripheral nerve

Authors' Afï¬liations: 1UMR_S745 INSERM, Universite Paris Descartes
Sorbonne Paris Cite, Faculte des Sciences Pharmaceutiques et Biologi-
ques; 2Department of Plastic and Reconstructive Surgery, H^opital Europeen
Georges Pompidou, Assistance Publique-H^opitaux de Paris (AP-HP), PRES
Sorbonne Paris Cite; 3Service d'Anatomie et Cytologie Pathologiques,
Assistance Publique-H^opitaux de Paris (AP-HP), H^opital Cochin, Universite
Paris Descartes; 4Service de Biochimie et de Genetique Moleculaire, H^opital
Cochin, Assistance Publique-H^opitaux de Paris (AP-HP); 5UMR8194
CNRS, PRES Sorbonne Paris Cite, Paris Descartes; 6Department of Ortho-
pedic Surgery, Cochin Hospital; 7Universite Paris Descartes, Sorbonne
Paris Cite, Faculte de Medecine, Assistance Publique-H^opitaux de Paris
(AP-HP), H^opital Cochin, Laboratory of Biochemistry; 8Tumour bank,
Cochin Hospital, Assistance Publique H^opitaux de Paris, Paris Descartes
University; 9INSERM, U1016, Institut Cochin, and CNRS, UMR8104, Paris;
10Departement de pathologie Assistance Publique-H^opitaux de Paris (AP-
HP) and Universite Paris Est Creteil
(UPEC); 11Platform of Biological
Ressources; 12Department of Plastic and Reconstructive Surgery, Assis-
tance Publique-H^opitaux de Paris (AP-HP) and Universite Paris Est Creteil

(UPEC), H^opital Henri-Mondor; 13Department of Dermatology, H^opital
Henri-Mondor, Assistance Publique-H^opitaux de Paris (AP-HP) and EA
4393 LIC, UPEC, Creteil, France; 14Laboratoire d'Oncogenetique, Institut
Curie, H^opital Rene Huguenin; FNCLCC, Saint-Cloud; and 15Genetics
Division, Department of Medicine, Brigham and Women's Hospital, and
Harvard Medical School, Boston, Massachusetts

Note: Supplementary data for this article are available at Clinical Cancer
Research Online (http://clincancerres.aacrjournals.org/).

Corresponding Author: Eric Pasmant, UMR_S745 INSERM, Universite
Paris Descartes Sorbonne Paris Cite, Faculte des Sciences Pharmaceu-
tiques et Biologiques, 4 avenue de l'Observatoire, 75006 Paris, France.
Phone: 33-1-53-73-97-25; Fax: 33-1-44-07-17-54; E-mail:
eric.pasmant@parisdescartes.fr

doi: 10.1158/1078-0432.CCR-13-0780
Ã“2013 American Association for Cancer Research.

358

Clin Cancer Res; 20(2) January 15, 2014

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Translational Relevance

The commonest neuroï¬bromatosis type 1 (NF1)-
associated tumors are nerve sheath tumors (NSTs: der-
mal or plexiform neuroï¬bromas), mainly composed of
Schwann cells. Plexiform neuroï¬bromas can undergo
malignant transformation to malignant peripheral nerve
sheath tumors with a poor vital prognosis. Little is
known of the genetic events required for neuroï¬bromas
formation or transformation. Here, we found that the
Wnt pathway was signiï¬cantly activated by quantifying
mRNAs of 89 Wnt pathway genes in 57 NF1-associated
NSTs. We then conï¬rmed that the knockdown of NF1 in
Schwann cells provoked the activation of Wnt pathway
by functional transfection assays. We showed that active
b-catenin protein expression was increased in NF1-
silenced cell lines. Wnt pathway activation was strongly
associated to both putative cancer stem cell reservoir and
Schwannâ€“mesenchymal transition. We highlighted the
implication of Wnt pathway in NF1 peripheral nerve
sheath tumorigenesis. Elucidation of the role of cellular
signaling pathways tumorigenesis will enable to estab-
lish molecular targeted therapeutics in NF1.

sheath tumors (neuroï¬bromas), which vary greatly in both
number and size, and may be dermal or plexiform (2).

Dermal neuroï¬bromas are typically small and grow as
discrete lesions in the dermis whereas plexiform neuroï¬-
bromas can develop internally along the plexus of major
peripheral nerves and become quite large. Plexiform neu-
roï¬bromas are probably derived from embryonic Schwann
cell lineage (3). During development, neural-crest cells
migrate along the peripheral nerves, and a subset of cells
commit to the Schwann cell lineage. Zheng and colleagues
demonstrated that plexiform neuroï¬bromas could origi-
nate from Nf1 deï¬ciency in fetal nonmyelinating Schwann
cells (4). Le and colleagues identiï¬ed a population of
progenitor cells residing in the dermis, termed "skin-derived
precursors" that form dermal neuroï¬bromas through loss
of Nf1 (5). These differences between dermal and plexiform
neuroï¬bromas suggest that the type of progenitor but also
the timing of somatic NF1 mutations may determine the
clinical course of these tumors (6).

In contrast to dermal neuroï¬bromas, plexiform neuroï¬-
bromas can undergo malignant transformation to malig-
nant peripheral nerve sheath tumors (MPNST) in about
10% of NF1 patients (7). Roughly half of all MPNSTs are
sporadic; they are found in patients who do not carry any
known genetic predisposition for cancer. The remaining
MPNSTs are found in patients who are diagnosed with NF1.
MPNSTs are resistant to conventional therapies, and their
deep-seated position and locally invasive growth hinder
complete surgical resection. The 5-year survival rate among
patients with MPNSTs ranges from 30% to 50%. In parallel
to the double inactivation of the NF1 gene, additional
genetic lesions seem necessary for malignant progression

Wnt Pathway Activation in NF1 Tumorigenesis

of plexiform neuroï¬bromas. TP53 mutations have been
identiï¬ed in MPNSTs but not in benign neuroï¬bromas,
indicating that the p53-mediated pathway is involved in
malignant progression (6, 8). Alterations of other genes
(p16/CDKN2A, p14/ARF, p27/KIP1, EGFR, mTOR) were also
detected in MPNST (9â€“12).

Although we have now identiï¬ed some of the genes that
when mutated initiate tumor formation and drive progres-
sion, the identity of the cell population(s) susceptible to
such transforming events remains undeï¬ned in the majority
of human cancers. Recent studies indicate that a small
population of cells (called cancer stem cells) endowed with
unique self-renewal properties and tumorigenic potential is
present in some, and perhaps, all tumors (13, 14). Many
signaling pathways involved in the maintenance of normal
stem cells are found to be altered in several human cancers
(i.e., Wnt, Hedgehog, and Notch pathways). Moreover,
several authors addressed the possible association between
the formation of stem cells and the epithelialâ€“mesenchymal
transition (EMT). Regulation of the EMT is a crucial step in
cancer development (15). Genetic alterations that impair
the differentiation program could endow such dedifferen-
tiated cells with attributes that mimic stem cell behavior.
In NF1 tumorigenesis, the question whether these tumors
arise from neural crest stem cells or differentiates glia
remains very controversial (4, 5, 16, 17). In this regard, we
have previously shown a dedifferentiation of Schwann cells,
as well as an activation of the Hedgehog signaling pathway,
during malignant transformation of plexiform neuroï¬bro-
mas (18). TWIST1, an important
transcription factor
involved in embryonic development and in EMT, was
shown to be upregulated in NF1-associated MPNST (19).
Taken together, these ï¬ndings suggest a genetic-driven
Schwannâ€“mesenchyme transition (SMT) that could gener-
ate cancer stem cells during NF1 tumorigenesis.

Wnt pathway is a major developmental pathway involved
in maintenance of normal stem cells (20), and altered in
several human cancers (21). Wnt signaling is a complex
process that requires interplay of many different proteins. In
addition to a large cohort of Wnt ligands, and frizzled
receptors, some Wnt pathways also require the presence of
coreceptors. Wnt ligands may activate 3 different pathways
(Supplementary Fig. S1): (i) the canonical pathway: involv-
ing b-catenin and LEF/TCF transcription factor; (ii) the
planar cell polarity pathway; and (iii) the Wnt/calcium
pathway (20, 22). All 3 pathways have different conse-
quences and drive speciï¬c processes for the cells in which
they signal.

Little is known of the additional cooperating genetic
events potentially required for full plexiform neuroï¬broma
formation. Furthermore, the respective tumorigenic mecha-
nisms of dermal neuroï¬bromas and plexiform neuroï¬bro-
mas have rarely been compared (6). In this manuscript we
addressed the potential role of Wnt signaling in NF1 tumor-
igenesis. We here quantiï¬ed the gene expression proï¬les of
89 actors of Wnt pathway in NF1-associated tumors.
We identiï¬ed speciï¬c genes involved in Wnt signaling
pathway whose expressions signiï¬cantly differed between

www.aacrjournals.org

Clin Cancer Res; 20(2) January 15, 2014

359

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Luscan et al.

3 NF1-associated tumor types: dermal and plexiform neu-
roï¬bromas and MPNSTs. We functionally conï¬rmed the
crosslink between NF1 alteration and Wnt pathway activa-
tion, using siRNA strategy in a cell line model. Finally, we
investigated the link between Wnt signaling pathway acti-
vation and the altered expression of stemness and SMT
genes.

Materials and Methods
Patients and samples

NF1-related samples were obtained by laser excision
(dermal neuroï¬bromas) or surgical excision (plexiform
neuroï¬bromas and MPNSTs) from patients with NF1 at
Henri Mondor Hospital (Creteil, France). Sample handling
and processing was identical for all NF1-related tumors.
After clinical examination, the surgical removal of dermal
neuroï¬bromas was proposed in case of esthetical burden.
Resection or removal of plexiform neuroï¬bromas was pro-
posed for repair or in case of symptoms, pain or compres-
sion. The plexiform neuroï¬bromas (deep lesions involving
a plexus of nerves) were large, had a nodular aspect, and
severely deformed the affected tissues. They were all S100-
positive by immunostaining. Four patients with plexiform
neuroï¬bromas had developed MPNSTs. The main clinical
and histological characteristics of the 16 patients with
MPNSTs (validation set) are shown in Supplementary Table
S1. Immediately after surgery the tumor samples were ï¬‚ash
frozen in liquid nitrogen and stored at  80

C until RNA
extraction. NF1-related MPNSTs all arose from plexiform
neuroï¬bromas and showed very weak S100 immunostain-
ing (data not shown). MPNST samples from non-NF1
patients were obtained by surgical excision at Cochin Hos-
pital (Paris, France). Dermal neuroï¬bromas were used as
"normal" control samples as they never undergo malignant
transformation in MPNSTs. Indeed, neuroï¬bromas are
heterogeneous benign tumors composed of Schwann cells,
ï¬broblasts, mast cells, and other cells, and have no "nor-
mal" tissue equivalent. Gene expression levels determined
by real time reverse transcription (RT)-PCR analysis in
plexiform neuroï¬bromas and MPNSTs were thus expressed
relative to expression levels in dermal neuroï¬bromas.

Cell lines

We analyzed 7 human MPNST cell lines, namely NMS-2,
NMS-2PC, 88-3, ST88-14, 90-8, S462, and T265. NMS-2
and NMS-2PC were kind gifts from Dr. Akira Ogose (Niigata
University School of Medicine, Niigata, Japan). 88-3, ST88-
14, and 90-8 were kind gifts from Dr. Nancy Ratner (Cin-
cinnati Childrenâ€™s Hospital Medical Center, Cincinnati,
OH). S462 was a kind gift from Dr. Lan Kluwe (University
Hospital Eppendorf, Hamburg, Germany). T265 was a kind
gift from Dr. G De Vries (Loyola University, Chicago, IL).
MPNST cell lines were grown in RPMI medium supplemen-
ted with 10% heat-inactivated FBS, 10 IU/mL penicillin,
and 10 mg/mL streptomycin. Normal Schwann cells and
ï¬broblasts were obtained by primary cell culture and dif-
ferential isolation from normal sciatic nerve biopsies and

skin, respectively, and using cell culture and isolation con-
ditions as previously described (23â€“25). Normal mast cells
were obtained by means of cell culture and various speciï¬c
puriï¬cation steps from cord blood-derived human cells, as
previously described (26).

We functionally analyzed the crosslink between NF1
alteration and the Wnt pathway using siRNA strategy in
the mouse Schwann cell line MSC80. MSC80 cells exhibit
normal Schwann cell characteristics (S100, myelin pro-
tein zero, peripheral myelin protein 22 expression) and
have retained the capacity to myelinate axons (27). The
mouse Schwann cell
line MSC80 was maintained in
Dulbeccoâ€™s minimal essential medium (DMEM) supple-
mented with 10% decomplemented fetal calf serum
(Hyclone-Perbio), 1% penicillin, 1% streptomycin
(Gibco), and 1% glutamine. Culture cells were grown at
37
C in a humidiï¬ed atmosphere of 5% CO2. A siRNA
strategy was also used in 2 human non-Schwann cell
lines: the breast cancer cell line, namely MCF-7 (Michigan
Cancer Foundation-7), and one embryonic kidney cell
line, namely HEK293 (Dr. FranÂ¸cois Lallemand, Institut
Curie, Saint-Cloud, France). We also analyzed mouse
embryonic ï¬broblasts (MEF) derived from wild-type mice
and from Nf1
mice (Dr. Thomas De Readt, Harvard
Medical School, Boston, MA).

 / 



Human mRNAs quantiï¬cation by real-time RT-PCR:
studied panels

We ï¬rst quantiï¬ed the mRNA expression level of the 89
Wnt pathway human genes in a series of 7 dermal neuroï¬-
bromas, 7 plexiform neuroï¬bromas, and 8 MPNSTs (screen-
ing set; N Â¼ 22 tumors). The 89 Wnt pathway quantiï¬ed
genes encode 19 Wnt ligands, 13 Wnt receptors, 32 proteins
involved in canonical Wnt signal transduction, 4 Wnt tran-
scription factors, 10 LEF/TCFâ€“inducible proteins (http://
www.stanford.edu/~rnusse/pathways/targets.html), and 11
proteins involved in noncanonical Wnt signal pathways
including 4 proteins involved in the planar cell polarity
pathway and 7 proteins in the Wnt/calcium pathway (Sup-
plementary Table S2). The mRNA expression of the 32
markedly differentially expressed genes was then determined
in a larger tumor series including 10 dermal neuroï¬bromas,
31 plexiform neuroï¬bromas, and 16 MPNSTs (validation set:
57 tumors). Expression of 2 major stem cell marker genes
(PROM1 and NKX2.2) and 5 major EMT marker genes
(TWIST1, SLUG, VIM, SNAIL, and CDH1) was also assessed
in the validation set (N Â¼ 57 tumors).

We then selected for further study the 24 genes whose
expression in the MPNST group and/or in the plexiform
neuroï¬broma group markedly differenced (>2-fold) from
that in the dermal neuroï¬broma group. Expression of the 24
genes was studied in normal human Schwann cells, ï¬bro-
blasts, endothelial cells, and mast cells, in 7 NF1-related
MPNST cell lines, in 4 sporadic MPNSTs, and in Nf1
and
Nf1
MEFs. Expression of the 24 genes was also studied in
the 2 human non-Schwann cell lines (HEK293 and MCF-7)
and one mouse Schwann cell line (MSC80) with siRNAs-
mediated NF1 knockdown.

Ã¾/Ã¾

 / 

360

Clin Cancer Res; 20(2) January 15, 2014

Clinical Cancer Research

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

mRNAs quantiï¬cation by real-time RT-PCR: method

We ï¬rst used real-time quantitative RT-PCR to quantify
the mRNA expression of 89 selected Wnt pathway asso-
ciated-genes in a series of MPNSTs and plexiform neuro-
ï¬bromas, by comparison with dermal neuroï¬bromas.
Quantitative RT-PCR is a major alternative to microarrays
for molecular tumor proï¬ling, being far more precise,
reproducible, and quantitative (28). Furthermore, it is
more appropriate for analyzing weakly expressed genes
such as the Wnt genes in this study. Finally, RT-PCR
requires smaller amounts of total RNA (about 2 ng per
target gene), which is more adapted for analyzing small-
sized tumors.

The theoretical and practical aspects of real-time quanti-
tative RT-PCR using the ABI Prism 7900 Sequence Detection
System (Perkin-Elmer Applied Biosystems) have been
described in detail elsewhere (28). We quantiï¬ed transcripts
of 2 endogenous RNA control genes involved in 2 cellular
metabolic pathways, namely TBP, which encodes the TATA
box-binding protein (a component of the DNA-binding
protein complex TFIID) and RPLP0 (also known as 36B4),
which encodes acidic ribosomal phosphoprotein P0. TBP
and RPLP0 were selected as endogenous controls because
the levels of their transcripts in the tumor samples were
low (Ct values between 24 and 26) and high (Ct values
between 18 and 20), respectively. Each sample was nor-
malized on the basis of its TBP (or RPLPO) content. Results,
expressed as N-fold differences in target gene expression
relative to the TBP (or RPLPO) gene, and termed "Ntarget,"
were determined as Ntarget Â¼ 2DCtsample , where the DCt value
of the sample was determined by subtracting the average Ct
value of the target gene from the average Ct value of the TBP
(or RPLP0) gene (29). The Ntarget values of the tumor
samples were subsequently normalized such that
the
mean of the dermal neuroï¬broma Ntarget values was 1.
Primers for TBP, RPLP0, and the target genes were chosen
with the assistance of the computer programs Oligo 6.0
(National Biosciences). For each primer pair, we performed
no-template control (NTC) and no-reverse-transcriptase
control (RT-negative) assays, which produced negligible
signals
suggesting that
primerâ€“dimer formation and genomic DNA contamination
effects were negligible. RNA extraction, cDNA synthesis,
and PCR reaction conditions have been described
elsewhere (29).

(usually >40 in Ct values),

Immunohistochemical study

Formalin ï¬xed, parafï¬n embedded skin samples were
retrieved from the archive material of the department of
Pathology of Henri Mondor Hospital. Hematoxylinâ€“eosinâ€“
saffron (HES) staining and immunohistochemistry were
applied to 3-mm-thick dewaxed sections. Immunostaining
of b-catenin (BD Biosciences Pharmingen) was done using
the Bond max device (Menarini diagnostics, France), at a
1:4,000 dilution after antigen retrieval by heat at pH 9. In all
samples, we checked the staining of epithelial (epidermis
or adnexae) and/or endothelial cells as internal positive
controls.

Wnt Pathway Activation in NF1 Tumorigenesis

HEK293, MCF-7, and MSC80 cells transfection with
siRNA

To knockdown the NF1 gene, human cell lines (HEK293
and MCF-7) and mouse cells (MSC80) transient transfec-
tions were carried out using Effecten reagent (Qiagen) for
MSC80, and Hiperfect Transfection Reagent (Qiagen)
according to HiPerFect Transfection Reagent Handbook for
human cell lines. SiRNAs were purchased from Qiagen:
mouse siRNA against Nf1 (reference GS18015), human
siRNA against NF1 (reference GS4763), and nontargeted
(NT) siRNAs (negative control reference 1027310). Mouse
Nf1 and human NF1 genes were targeted with 4 different
sequences of siRNA directed against 4 different regions of
the cognate mRNA. We quantiï¬ed gene expressions at both
mRNA (using real-time RT-PCR) and protein (using West-
ern blot) levels to assess the siRNAs efï¬cacy.

Luciferase reporter assay of b-cateninâ€“mediated Wnt
signaling pathway activation

Luciferase reporter assay was used to determine the Wnt
pathway signaling activity in Nf1 invalidated or in control
(nontargeting; NT) siRNAs MSC80 cells. SuperTOP-Flash-
Luc plasmids were kindly provided by Dr. R T Moon
(University of Washington School of Medicine, Seattle,
WA). One day before transfection, MSC80 cells (1.5 
105 cells per well) were seeded into 6-well plate and incu-
bated in the DMEM culture medium containing 10%
decomplemented fetal calf serum. SuperTOP-Flash-Luc
plasmid (0.4 mg), the pCMV-b-galactosidase expression
vector (0.1 mg), and siRNAs (25 nmol/L) were mixed with
a solution containing Effecten reagents (0.85 mg/mL) in
DMEM. The mixture was then added to the cells and
incubated overnight. Sixteen hours after transfection, the
medium was replaced by DMEM culture medium contain-
ing 10% decomplemented fetal calf serum. Luciferase activ-
ity was determined using an enzymatic method described
by Massaad and colleagues (30). The b-galactosidase activ-
ity was used for the transfection efï¬ciency normalization.

Protein extraction and Western blot analysis



Cells transfected with NT siRNA or with siRNAs against
NF1 were homogenized in 100 mL ice-cold RIPA buffer [50
mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 0.1% SDS,
0.5% sodium deoxycholate, 1% NP-40, 5 mmol/L EDTA,
pH 8.0, 2 mmol/L phenylmethylsulfonylï¬‚uoride (PMSF;
Sigma-Aldrich), 50 mg/mL leupeptin, 50 mg/mL pepstatin A,
and 50 mg/mL aprotinin]. Protein concentration of the
clariï¬ed homogenates (4
C, 15 minutes, 13,500 rev/min)
was determined on all samples using the Bradford protein
assay (Bio-Rad Laboratories). Aliquots of 30 mg of total
protein extracts were used for each sample. Homogenate
proteins were separated on 15% SDS-PAGE gel or on Pre-
cast XT 4% to 12% Bis-Tris Criterion Gel (Bio-Rad) for
neuroï¬bromin and blotted onto polyvinylidene diï¬‚uoride
membranes. Nonspeciï¬c binding sites in the transblots

were blocked at 4
C overnight with 5% bovine serum
albumin (BSA), 0.01% Tween 20 (Invitrogen), TBS, pH
7.4. Membranes were then incubated at room temperature

www.aacrjournals.org

Clin Cancer Res; 20(2) January 15, 2014

361

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Luscan et al.

for 2 hours with the following primary antibodies diluted in
a mixture of 5% BSA blocking agent and TBS-Tween 0.1%:
active (dephospho) b-catenin (anti-ABC) clone 8E7 anti-
body (1:1,000), b-catenin antibody (1:1,000), neuroï¬bro-
min antibody (1:1,000), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antibody (1:10,000). They were
then incubated at room temperature for 1 hour 30 minutes
with the appropriate secondary antibody diluted in 5% BSA
blocking buffer/TBS-Tween 0.1% (anti-mouse and anti-
rabbit at 1:20,000), followed by ECL Plus Western blotting
detection (Amersham) before exposure to radiographic ï¬lm
Hyperï¬lm ECL (Amersham). Western blots were quantiï¬ed
by means of NIH Image J Software.

Primary antibodies against neuroï¬bromin (rabbit mono-
clonal antibody) were purchased from Santa-Cruz (refer-
ence sc67), mouse total b-catenin (mouse monoclonal
antibody) was purchased from BD Biosciences, human total
b-catenin (rabbit polyclonal antibody) was purchased from
Cell Signaling (reference #9562), active-b-catenin (mouse
monoclonal antibody) and GAPDH (mouse monoclonal
antibody) were purchased from Millipore (reference 05-665
and G8795). Secondary antibodies used for Western blot-
ting were horseradish peroxidaseâ€“conjugated goat anti-
mouse and anti-rabbit immunoglobulin G (Millipore).

Statistical analysis

As mRNA levels did not ï¬t a Gaussian distribution, (i)
mRNA levels in each subgroup of samples were expressed as
their median values and ranges, rather than their mean
values and coefï¬cients of variation; and (ii) comparison
and relationships between mRNA levels of the different
target genes were respectively estimated using nonparamet-
ric tests: the Mannâ€“Whitney U test (link between 1 quali-
tative parameter and 1 quantitative parameter) and the
Spearman correlation test (link between 2 quantitative
parameters). Differences between the 2 populations were
judged signiï¬cant at conï¬dence levels greater than 95% (P <
0.05). In the SuperTOP-Flash Luciferase reporter assay, 2
groups comparisons were performed by the Student T test. A
P-value of <0.05 was considered to be statistically
signiï¬cant.

Results
mRNA expression of 89 Wnt pathway genes in 7 dermal
neuroï¬bromas, 7 plexiform neuroï¬bromas, and 8
MPNST NF1-related samples (screening set)

Eight (9%) of the 89 genes (i.e., WNT1, WNT7A, WNT8A,
WNT8B, WNT9B, DKK4, KREMEN2, and TLE1) showed
very low levels of target gene in dermal neuroï¬bromas,
plexiform neuroï¬bromas, and MPNSTs. Their mRNA levels
were only detectable but not reliably quantiï¬able by means
of real-time quantitative RT-PCR assays, mainly based on
ï¬‚uorescence SYBR Green methodology (Ct > 32). Thirty-
two (39.5%) of the 81 remaining genes were expressed at a
level (>2-fold) in the MPNST group and/or
different
the plexiform neuroï¬bromas group compared with the
dermal neuroï¬bromas group: 9 genes were deregulated in

the 7 plexiform neuroï¬bromas as compared with the 7
dermal neuroï¬bromas and 30 genes in the 8 MPNSTs as
compared with the 7 dermal neuroï¬bromas (Supplemen-
tary Table S3).

mRNA expression of 32 identiï¬ed Wnt pathway genes
in 10 dermal neuroï¬bromas, 31 plexiform
neuroï¬bromas, and 16 MPNST NF1-related samples
(validation set)

Expression levels of the 32 deregulated genes identiï¬ed by
"screening set" analysis were then determined in 10 dermal
neuroï¬bromas, 31 plexiform neuroï¬bromas, and 16
MPNST samples. Nine (28.1%) of the 32 genes were sig-
niï¬cantly deregulated in the 31 plexiform neuroï¬bromas
as compared with the 10 dermal neuroï¬bromas (P <
0.05; Fig. 1 and Supplementary Table S4): 8 genes were
upregulated (WNT9A, FZD1, SFRP4, SFRP5, TLE2, MYC,
CAMK2B, and PRKCQ) and 1 was downregulated (SFRP1)
in plexiform neuroï¬bromas. These 9 deregulated genes in
plexiform neuroï¬bromas encode 1 Wnt ligand (WNT9A), 1
Wnt receptor (FZD1), 4 proteins involved in canonical Wnt
signal transduction (SFRP1, SFRP4, SFRP5, and TLE2), 1
LEF/TCF-inducible protein (MYC), and 2 proteins involved
in the Wnt/calcium pathway (CAMK2B and PRKCQ).

Twenty (62.5%) of the 32 genes were signiï¬cantly deregu-
lated in the 16 MPNSTs as compared with the 10 dermal
neuroï¬bromas (P < 0.05; Fig. 1; Supplementary Table S4):
14 genes were upregulated (WT5A, FZD1, FZD8, DKK1,
WIF1, LEF1, ID2, MSX2, SOX9, WISP1, TWIST1, BMP2,
CAMK2B, and PRKCQ) and 6 were downregulated (WNT2,
WNT9A, DKK3, KREMEN1, SFRP1, and TCF7) in MPNSTs.

Figure 1. Diagram depicting P values (horizontal bars) for signiï¬cant
gene expression differences between MPNSTs and/or plexiform
neuroï¬bromas (PNF) and dermal neuroï¬bromas. Arrows indicate
increased (up arrow) or decreased (down arrow) differential expression.

362

Clin Cancer Res; 20(2) January 15, 2014

Clinical Cancer Research

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

These 20 deregulated genes in MPNSTs encode 3 Wnt
ligands (WNT2, WNT5A, and WNT9A), 2 Wnt receptors
(FZD1 and FZD8), 5 proteins involved in canonical Wnt
signal transduction (DKK1, DKK3, KREMEN1, SFRP1, and
WIF1), 2 transcription factors (LEF1 and TCF7), 6 LEF/TCF-
inducible proteins (ID2, MSX2, SOX9, WISP1, TWIST1, and
BMP2), and 2 proteins involved in the Wnt/calcium path-
way (CAMK2B and PRKCQ).

Taken together, our results showed that 4 genes were
speciï¬cally deregulated in plexiform neuroï¬bromas, 15
were speciï¬cally dysregulated in MPNSTs, and 6 were dys-
regulated in both tumor types.

In the same set of 57 samples, we also examined the
expression of the NF1 gene, and the proliferation-asso-
ciated gene MKI67 that encodes the proliferation-related
antigen Ki-67. NF1 expression was similar in the 3 groups
of tumors whereas MKI67 showed signiï¬cant overexpres-
sion (30.5-fold) in MPNSTs (P Â¼ 0.00005; Fig. 1 and
Supplementary Table S4). This lack of expression differ-
ence for NF1 is probably because of the fact that the NF1
gene is ubiquitously expressed and therefore expressed in
the different cell components of the neuroï¬bromas and
MPNSTs, and that NF1
Schwann cells represent only a
fraction of the total Schwann cell population in tumor
samples.

The immunohistochemical study of b-catenin in MPNSTs
showed a strong diffuse and cytoplasmic staining (Fig. 2). In

 / 

Wnt Pathway Activation in NF1 Tumorigenesis

contrast, a weaker b-catenin staining was observed in the
plexiform neuroï¬bromas (Fig. 2).

mRNA expression of 32 identiï¬ed Wnt pathway genes
in paired plexiform neuroï¬broma and MPNST samples
from 4 patients

We analyzed the mRNA levels of the 32 deregulated genes
identiï¬ed by "screening set" analysis in 4 patients from
whom both plexiform neuroï¬broma and matched MPNST
samples were available. We found a clear decrease in the
mRNA level of WNT9A, DKK3, SFRP4 (all patients), and
WISP1 (patients 1, 3, and 4), upon progression from
plexiform neuroï¬broma to MPNST (Supplementary Fig.
S2). We also found a clear increase in the mRNA level of
DKK1 (all patients), TLE2, TCF7, WNT2 (patients 1, 2, and
3), and WNT5A (patients 3 and 4) during this transition
(Supplementary Fig. S2).

mRNA expression of the 24 differentially expressed
Wnt pathway genes in 4 non-NF1 (sporadic) MPNSTs
The expression levels of the 24 differentially expressed
Wnt pathway genes were also determined in 4 non-NF1
(sporadic) human MPNST biopsies (Supplementary Table
S5). According with the data obtained in NF1-associated
MPNSTs, the majority of the 14 genes upregulated and of
the 6 downregulated in MPNST biopsies showed a trend to
be also up- and downregulated.

A

B

C

Figure 2. Representative immunohistochemical study of b-catenin in MPNST and plexiform neuroï¬broma. A, this tissue sample shows an area of plexiform
neuroï¬broma surrounding the MPNST (arrows). The MPNST shows an intense b-catenin staining (left: hematoxylin, eosin, and saffron stain; right:
immunohistochemistry revealed by diaminobenzindine, original magniï¬cations 25). B, the MPNST areas show a diffuse and cytoplasmic expression
of b-catenin (left: hematoxylin, eosin, and saffron stain; right: immunohistochemistry revealed by diaminobenzindine, original magniï¬cations 200).
C, the plexiform neuroï¬bromas show a weak cytoplasmic expression of b-catenin in a proportion of Schwann cells, whereas intratumoral vessels are
strongly stained, taken as internal positive controls (left: hematoxylin, eosin, and saffron stain; right: immunohistochemistry revealed by diaminobenzindine,
original magniï¬cations 200).

www.aacrjournals.org

Clin Cancer Res; 20(2) January 15, 2014

363

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Luscan et al.

mRNA expression of the 24 differentially Wnt pathway
expressed genes in normal human Schwann cells,
ï¬broblasts, endothelial cells, and mast cells

Neuroï¬bromas and MPNSTs are both heterogeneous
tumors mainly composed of Schwann cells (60â€“80%),
together with ï¬broblasts, mast cells, and endothelial cells
(3). To investigate cell typeâ€“speciï¬c expression of the 24
previously identiï¬ed altered genes in NF1 plexiform neu-
roï¬bromas and/or MPNSTs (Fig. 1 and Supplementary
Table S4), we analyzed their mRNA levels by means of
real-time RT-PCR in normal human Schwann cells, ï¬bro-
blasts, endothelial cells, and mast cells (Table 1). MYC,
CAMK2B, KREMEN1, and BMP2 were similarly expressed
in the 4 cell types, suggesting a ubiquitous expression. TLE2,
DKK3, TCF7, FZD1, FZD8, and DKK1 were similarly
expressed in Schwann cells, ï¬broblasts, and endothelial

cells, but were not expressed in mast cells. Six of these
24 genes (WISP1, WNT5A, SFRP1, ID2, TWIST1, and SOX9)
were similarly expressed in Schwann cells and ï¬broblasts,
but were not expressed (Ct > 32) in endothelial cells or
mast cells. WNT2, MSX2, LEF1, SFRP4, and SFRP5 were
Schwann cellâ€“speciï¬c, being expressed more than 20
times in the Schwann cells than in the other 3 cell types.
PRKCQ was mainly expressed in endothelial cells and
mast cells, and WIF1 only in Schwann cells and endo-
thelial cells. Finally, WNT9A was endothelial cells speciï¬c
(being expressed 10 times more than in the other 3 cell
types). It is noteworthy that the endothelial cells speci-
ï¬city of WNT9A could explain its expression proï¬le in
NF1 tumors, in particular its overexpression in plexiform
neuroï¬bromas (well-known to be more angiogenic than
the dermal neuroï¬bromas).

Table 1. mRNA expression of 24 identiï¬ed genes in normal human cells

Mast cells

Schwann cells

Fibroblasts

Endothelial cells

0.00
39.80
0.03

1.30
0.21

930.00
0.64
0.40
0.27
0.02
0.00
0.30
0.00

0.00
0.72

17.90
0.00
0.45
0.31
5.16
7.02
5.96

0.46
0.00

0.00
0.20
0.47

0.13
0.87

396.00
0.29
0.10
0.02
0.00
0.03
0.41
0.60

0.01
0.20

0.19
0.04
0.56
0.00
0.02
0.01
21.38

2.46
1.11

0.28a
33.84
0.04

0.44
3.70

486.00
3.71
0.13
0.55
0.83
0.62
0.11
1.05

0.00
0.00
0.01

Wnt ligands (n Â¼ 3)
WNT2
WNT5A
WNT9A
Wnt receptors (n Â¼ 2)
FZD1
0.03
FZD8
0.00
Wnt signal transduction (n Â¼ 8)
DKK1
0.00
DKK3
0.01
0.03
KREMEN1
SFRP1
0.00
SFRP4
0.00
SFRP5
0.00
TLE2
0.00
WIF1
0.00
Wnt transcriptional factors (n Â¼ 2)
LEF1
0.00
TCF7
0.00
Lef/Tcf-inducible proteins (n Â¼ 7)
ID2
0.18
MSX2
0.00
0.55
MYC
SOX9
0.00
WISP1
0.00
TWIST1
0.00
BMP2
0.40
Noncanonical Wnt signal: Wnt/calcium pathway (n Â¼ 2)
CAMK2B
PRKCQ

0.60
2.28

0.38
0.40

2.84
0.96
0.82
0.93
10.65
0.60
0.30

1.26
0.08

NOTE: The gene mRNA levels (calculated as described in Materials and Methods) were based on the amount of the target message
relative to the endogenous control TBP message, in order to normalize the starting amount and quality of total RNA. Similar results were
obtained with a second endogenous control, the RPLP0 gene (also known as 36B4).
Genes indicated in bold were found to be highly expressed as compared with one or several other normal human cells.
aFor each gene, mRNA levels were normalized to the 10 dermal neuroï¬bromas.

364

Clin Cancer Res; 20(2) January 15, 2014

Clinical Cancer Research

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Wnt Pathway Activation in NF1 Tumorigenesis

mRNA expression of the 24 differentially expressed
Wnt pathway genes in 7 NF1-associated MPNST cell
lines

The expression levels of the 24 identiï¬ed genes was
determined in 7 well-characterized NF1-associated MPNST
cell lines, namely NMS-2, NMS-2PC, 88-3, ST88-14, 90-8,
S462, and T265 (Table 2). All genes (except WT9A in
agreement with the fact that it is an endothelial cellâ€“
speciï¬c gene) were expressed (Ct < 32) in at least 1 NF1-
associated MPNST cell
line. According with the data
obtained in MPNSTs, the majority of the 14 genes upre-
gulated and of the 6 downregulated in MPNST biopsies
was also up- and downregulated (>3-fold the median
value in 10 dermal neuroï¬bromas) in a fraction of the
MPNST cell lines. For example, WT5A, FZD8, DKK1,
WIF1, MSX2, and CAMK2B were upregulated in at least
5 of the 7 MPNST cell lines, whereas WNT2, WNT9A,
DKK3, KREMEN1, and SFRP1 were downregulated in at
least 5 of the 7 MPNST cell lines. These ï¬ndings conï¬rm

the Schwann cell expression of these genes and their
dysregulation in MPNST tumorigenesis.

Relationship between mRNA levels of 24 differentially
expressed Wnt pathway genes and 2 major stem cell
markers (PROM1 and NKX2.2)

Several studies supported the role of the canonical Wnt
signaling in the formation and maintenance of stem cells
and cancer stem cells (14, 20â€“22). To explore the possible
involvement of the 24 identiï¬ed Wnt genes (deregulated in
NF1 tumors) in the formation of cancer stem cells, we tested
the relationship between the expression of these 24 differ-
entially expressed Wnt genes and 2 major stem cell marker
genes, that is PROM1 (also known as CD133) and NKX2-2,
in our series of 57 NF1-associated tumors. PROM1 and
NKX2-2 were overexpressed (144- and 87-fold, respectively)
in MPNSTs (P Â¼ 0.0007 and 0.002, respectively; Mannâ€“
Whitney U test) suggesting an increase of the proportion of
cancer stem cells in this malign tumor group. We observed

Table 2. mRNA expression of 24 identiï¬ed genes in 7 NF1-associated MPNST cell lines

NMS-2

NMS-2PC

88-3

ST88-14

90-8

S462

T265

0.09
12.65
0.01

0.44
3.56

796.00
0.23
0.12
0.42
0.00
0.57
0.22
27.2

0.24
0.75

1.17
11.80
1.59
1.80
0.11
0.31
13.18

4.08
3.36

0.32
8.79
0.08

1.33
4.17

6146.00
0.91
0.45
0.29
0.01
0.63
0.79
96.8

0.61
1.75

0.76
8.00
0.35
5.09
0.00
3.50
5.18

0.00
6.16

0.04
1.42
0.20

0.56
6.93

1252.00
0.17
0.14
0.28
0.00
0.00
0.67
48.3

0.33
0.77

0.35
3.28
1.73
2.43
1.20
0.71
0.86

3.54
1.92

0.18
1.13
0.07

0.21
0.22

806.00
0.03
0.05
0.15
0.00
1.19
0.38
30.0

0.55
0.14

1.30
4.80
3.96
0.24
0.12
1.39
0.20

0.00
1.95

0.44
16.15
0.05

0.32
5.38

1648.00
0.23
0.11
0.05
0.01
0.88
0.12
25.8

0.20
0.45

0.95
2.46
1.84
1.12
0.02
0.56
4.48

3.48
2.00

0.04
11.52
0.00

0.96
3.99

0,08a
5.76
0.04

1.21
0.45

716.00
0.10
0.36
0.14
0.04
0.70
0.35
37.4

868.00
0.12
0.13
0.04
0.02
2.71
0.11
35.7

Wnt ligands (n Â¼ 3)
WNT2
WNT5A
WNT9A
Wnt receptors (n Â¼ 2)
FZD1
FZD8
Wnt signal transduction (n Â¼ 8)
DKK1
DKK3
KREMEN1
SFRP1
SFRP4
SFRP5
TLE2
WIF1
Wnt transcriptional factors (n Â¼ 2)
LEF1
TCF7
Lef/Tcf-inducible proteins (n Â¼ 7)
ID2
MSX2
MYC
SOX9
WISP1
TWIST1
BMP2
Noncanonical Wnt signal: Wnt/calcium pathway (n Â¼ 2)
CAMK2B
PRKCQ

3.25
38.20
1.64
1.25
0.18
1.31
0.92

0.41
14.00
1.52
4.86
0.86
1.20
0.96

18.36
0.91

12.18
3.13

0.63
0.88

0.98
1.00

NOTE: The genes indicated in bold were found to be differentially expressed.
aFor each gene, mRNA levels were normalized to the 10 dermal neuroï¬bromas.

www.aacrjournals.org

Clin Cancer Res; 20(2) January 15, 2014

365

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Luscan et al.

Table 3. Relationship between mRNA levels of the 24 identiï¬ed genes and stem cell marker and EMT
marker genes

EMT markers

SLUG

CDH1

NS

NS

NS

NS
NS

NS

NS

NS

NS
 0.337
P Â¼ 0.024
 0.322
P Â¼ 0.014
NS
Ã¾0.392
P Â¼ 0.003

NS
NS

NS
Ã¾0.293
P Â¼ 0.02
NS

NS
Ã¾0.305
P Â¼ 0.02
Ã¾0.289
P Â¼ 0.028
Ã¾0.505
P Â¼ 0.00009

NS

NS

NS

NS
 0.278
P Â¼ 0.03

NS

NS
Ã¾0.371
P Â¼ 0.0046
NS

NS

NS

NS
NS

NS
NS

NS

NS

NS

NS

NS

NS

NS

NS

Stem cell markers

Wnt ligands (n Â¼ 3)
WNT2

WNT5A

PROM1

 0.355a
P Â¼ 0.007b
Ã¾0.484
P Â¼ 0.0002
 0.319
P Â¼ 0.015

WNT9A
Wnt receptors (n Â¼ 2)
NS
FZD1
Ã¾0.398
FZD8
P Â¼ 0.02
Wnt signal transduction (n Â¼ 8)
Ã¾0.610
DKK1
P Â¼ 0.000001
 0.386
P Â¼ 0.003
 0.439
P Â¼ 0.0008
NS

KREMEN1

SFRP1

DKK3

SFRP4

SFRP5

NS

NS

TLE2
NS
Ã¾0.527
WIF1
P Â¼ 0.00004
Wnt transcriptional factors (n Â¼ 2)
LEF1
NS
 0.520
TCF7
P Â¼ 0.00006
Lef/Tcf-inducible proteins (n Â¼ 7)
Ã¾0377
ID2
P Â¼ 0.004
Ã¾0.573
P Â¼ 0.000007
NS

MSX2

MYC

NKX2-2

 0.365
P Â¼ 0.005
Ã¾0.353
P Â¼ 0.007
 0.406
P Â¼ 0.002

NS
NS

Ã¾0.385
P Â¼ 0.003
 0.413
P Â¼ 0.0015
 0.327
P Â¼ 0.01
NS
 0.296
P Â¼ 0.024
NS

NS
Ã¾0.609
P Â¼ 0.000001

NS
 0.400
P Â¼ 0.002

NS
Ã¾0.384
P Â¼ 0.003
NS

SOX9

WISP1

TWIST1

NS
Ã¾0.418
P Â¼ 0.001
NS
Ã¾0.314
BMP2
P Â¼ 0.017
Noncanonical Wnt signal: Wnt/calcium pathway (n Â¼ 2)
CAMK2B

NS
Ã¾0.630
P Â¼ 0.0000005
NS
Ã¾0.291
P Â¼ 0.027
Ã¾0.314
P Â¼ 0.017

NS

TWIST1

Ã¾0.285
P Â¼ 0.03
NS

NS

NS
Ã¾0.468
P Â¼ 0.0003
Ã¾0.318
P Â¼ 0.015
NS

NS
Ã¾0.342
P Â¼ 0.009
NS

NS

NS
Ã¾0.307
P Â¼ 0.019

NS
NS

Ã¾0.360
P Â¼ 0.006
Ã¾0.433
P Â¼ 0.0009
Ã¾0.305
P Â¼ 0.02
Ã¾0.344
P Â¼ 0.009
Ã¾0.309
P Â¼ 0.018
Ã¾1.000
 7
P < 10
Ã¾0.377
P Â¼ 0.0039

NS

NS

(Continued on the following page)

366

Clin Cancer Res; 20(2) January 15, 2014

Clinical Cancer Research

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Wnt Pathway Activation in NF1 Tumorigenesis

Table 3. Relationship between mRNA levels of the 24 identiï¬ed genes and stem cell marker and EMT marker
genes (Cont'd )

Stem cell markers

PROM1
NS

NKX2-2
NS

PRKCQ

TWIST1
Ã¾0.260
P Â¼ 0.048

EMT markers

SLUG
Ã¾0.312
P Â¼ 0.017

CDH1
NS

Abbreviation: NS, not signiï¬cant.
aSpearman correlation coefï¬cient.
bP value, Spearman rank correlation test.
The genes indicated in bold were found to be marked signiï¬cantly differentially expressed (P < 0.01).

high statistical signiï¬cant positive associations between
PROM1 and NKX2-2, and WNT5A, DKK1, WIF1, MSX2,
and WISP1 (P < 0.01 with both PROM1 and NKX2-2), and
high statistical signiï¬cant negative associations between
PROM1 and NKX2-2, and WNT2, DKK3, KREMEN1, and
TCF7 (P < 0.01 with both PROM1 and NKX2-2; Table 3).

Relationship between mRNA levels of 24 differentially
Wnt pathway expressed genes and 5 major EMT
markers (TWIST1, SLUG, SNAIL, VIM, and CDH1)

Regulation of the EMT is a crucial step in cancer devel-
opment. TWIST1, an important
transcription factor
involved in EMT and upregulated in NF1-associated MPNST
(19), is also a major LEF/TCFâ€“inducible gene (http://www.
stanford.edu/~rnusse/pathways/targets.html).
In conse-
quence, to explore the involvement of the Wnt pathway in
a possible Schwannâ€“mesenchymal transition during NF1
tumorigenesis, we ï¬rst tested the expression of 5 major EMT
markers (TWIST1, SLUG, SNAIL, VIM, and CDH1) in our
series of 57 NF1-associated tumors. TWIST1 and SLUG were
overexpressed (1.6- and 2.1-fold, respectively) in the
MPNSTs (P Â¼ 0.005 and 0.001, respectively), whereas
CDH1 was underexpressed (11-fold; P Â¼ 0.0006). SNAIL
and VIM showed similar mRNA levels in dermal neuroï¬-
bromas, plexiform neuroï¬bromas, and MPNSTs. We next
tested the relationship between the expression of the 24
identiï¬ed Wnt genes and of the 3 differentially expressed
EMT marker genes (i.e., TWIST1, SLUG, and CDH1). We
observed high statistical signiï¬cant positive associations
(P < 0.01) between TWIST1 and FZD8, SFRP1, ID2, MSX2,
SOX9, and BMP2, between SLUG and WIF1 and BMP2, and
between CDH1 and KREMEN1. CDH1 and KREMEN1
showed a correlated decreased expression in MPNSTs
(Table 3). It is noteworthy that we observed a high statistical
signiï¬cant positive association between SLUG and both
PROM1 and NKX2-2 (P Â¼ 0.0033 and 0.00068,
respectively).

In vitro consequences of NF1 inactivation on Wnt
pathway activation state

To analyze the effects of the NF1 gene inactivation on the
Wnt pathway, we knocked down the expression of NF1 in 2
human cell lines (an embryonic kidney cell line: HEK293

and a breast adenocarcinoma cell line: MCF-7) and 1 mouse
Schwann cell line (MSC80) by siRNAs strategy. Cells were
transfected with either a nontargeting siRNA (NT) or a
siRNA directed against NF1. The efï¬cacy of the knockdown
of the NF1 expression was tested by real-time RT-PCR and
Western blot. In MSC80 cell line, we found a decreased Nf1
expression at both mRNA and protein (neuroï¬bromin)
levels (Fig. 3A). In human cell lines (HEK293 and MCF-
7), a decreased NF1 expression was conï¬rmed at mRNA
level (data not shown).

In the 2 human cell lines (HEK293 and MCF-7), mRNA
expression of 24 Wnt pathway genes (cf. supra) was ana-
lyzed after the knockdown of NF1. Those 2 non-Schwann
cell lines showed no clear Wnt gene expression difference
for the majority of the 14 upregulated and the 6 down-
regulated genes in MPNST biopsies and no difference was
found in the amount of the active as well as the total
b-catenin quantiï¬ed by Western blot (data not shown).

Similarly, no clear expression difference was found
between the MEFs derived from wild-type mice and the
MEFs derived from Nf1
mice, in the majority of the 14
upregulated and of the 6 downregulated genes in MPNST
biopsies (data not shown).

 / 

In MSC80 Schwann cells, we used a Wnt pathway reporter
assay to determine whether the canonical Wnt signaling
pathway was modulated after the knockdown of Nf1. The
silencing of Nf1 increased by 3-folds (P < 0.01) the pro-
moter activity of SuperTOP-Flash-Luc in MSC80 (Fig. 3B).
The knockdown of Nf1 did not alter the promoter activity of
SuperFOP-Flash-Luc, a construct that lacks any binding sites
for TCF/LEF transcription factors (Fig. 3B). Furthermore,
the transcript of Axin2, a target gene of Wnt pathway was
increased by 2-folds after the silencing of Nf1 in MSC80 cells
(Fig. 3C). To assess whether the knockdown of Nf1 altered
the expression of b-catenin at the protein level, we have
quantiï¬ed by Western blot the amount of the active as well
as the total b-catenin. In MSC80 transfected with the siRNA
against Nf1, we observed a 2-folds increase of the ratio of
active-b-catenin/total-b-catenin compared with the control
cells (Fig. 3D).

Altogether, those data show that the knockdown of
NF1 in Schwann cells enhances the activity of Wnt/b-cate-
typeâ€“speciï¬c
nin pathway. Those data suggest

cell

www.aacrjournals.org

Clin Cancer Res; 20(2) January 15, 2014

367

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Luscan et al.

A

C

)

i

s
6
2
/
2
n
x
a
 
s
t
p
i
r
c
s
n
a
r
T

%

(

siNF1

NT

NF1

GAPDH

250

200

150

100

50

0

NT

siNF1

B

n
o
i
t
a
v
i
t
c
a
s
n
a
r
T
%

 

D

l

i

 
e
a
t
o
t
/
n
n
e
t
a
c
-
Î²
 
e
v
i
t
c
A

i

n
n
e
t
a
c
-
Î²

400

300

200

100

0

250

200

150

100

50

0

SuperTop-Flash

SuperTop-Flash

NT

siNF1

siNF1

NT

siNF1

Figure 3. Effect of Nf1 knockdown on Wnt pathway in MSC80 cells. A, MSC80 cells were transfected with either siRNA-targeting NF1 or nontargeting siRNA
(NT). Western blots using anti-neuroï¬bromin antibodies were perfomed to verify Nf1 inactivation at protein level in MSC80 cells. GAPDH was used to normalize
the Western blots. Results were reproduced in 3 independent experiments, and ï¬gures represent a typical experiment. B, MSC80 cells were transiently
cotransfected by the SuperTOP-Flash Luciferase or SuperFOP-Flash Luciferase plasmids with either nontargeting (NT) siRNA or siRNA against NF1.
Luciferase activity was then analyzed. , P < 0.05, and , P < 0.01 by Tukey post hoc tests after one-way ANOVA when compared with control. C, MSC80 cells
were transfected with either NT or a siRNA against Nf1. Total RNA was extracted and RT-qPCR was performed using speciï¬c primer recognizing Axin2. D,
Western blots were performed using anti-active (dephosphorylated b-catenin) and anti-total b-catenin antibodies. GAPDH was used to normalize the Western
blots. The Western blots were quantiï¬ed using Image J software (rsb.info.nih.gov).

consequences of NF1 knockdown as Wnt pathway activa-
tion was not observed in epithelial (MCF-7) or kidney
(HEK293) cell lines, or in MEFs cells but only in Schwann
(MSC80) cell lines.

Discussion

WNT signaling pathway orchestrates highly complex
molecular events. Aberrant activation of Wnt pathway could
trigger cell malignant transformation. In the last 20 years,
involvement of the Wnt pathway has mainly been revealed
in human epithelial malignancies (31). However, the Wnt
pathway may also play a role in tumors of mesenchymal
origin (32). Mesenchymal stem cells could differentiate into
Schwann cellâ€“like cells (33). In this work, we therefore
apprehended the role of Wnt pathway in NF1 tumorigenesis
and more particularly its link with cancer stem cells and
putative Schwannâ€“mesenchymal transition.

Wnt pathway is tightly implicated in the myelination
process elicited by Schwann cells. We have shown that the
selective inhibition of Wnt components by siRNA or dom-
inant negative forms inhibits the expression of myelin genes
in mouse Schwann cells (34, 35). Moreover, the activation
of Wnt signaling by recombinant Wnt ligands increases the
transcription of myelin genes. Importantly, loss-of-function
analyses in zebraï¬sh embryos show, in vivo, a key role for

Wnt/b-catenin signaling in the initiation of myelination
and in myelin sheath compaction in the central and periph-
eral nervous systems. Inhibition of Wnt/b-catenin signaling
resulted in hypomyelination, without affecting Schwann
cells and oligodendrocytes generation or axonal integrity
(21). Thus, the dysregulation of this pathway could lead to
either developmental defects or tumorigenesis.

Nine genes were signiï¬cantly deregulated in plexiform
neuroï¬bromas (as compared with dermal neuroï¬bromas):
8 genes were upregulated and 1 was downregulated
(Table 4). All these genes (except WNT9A, which seems
endothelial cell speciï¬c) were expressed in normal and
tumoral Schwann cells (Table 2). Our results show that
among the 3 different Wnt pathways, the canonical Wnt
pathway is mainly involved in plexiform neuroï¬broma
development with deregulation of genes encoding major
components of this Wnt pathway (Table 4). Little is known
about the relevance of these genes (except MYC) to cancer
biology. A few observations have however described impli-
cations of these genes in several cancer types (36â€“40). Taken
together, these ï¬ndings suggest an alteration of the canon-
ical Wnt pathway FZD1/SFRP1/TLE2/MYC in plexiform
neuroï¬broma development.

Our results also showed a major activation of the Wnt
canonical pathway during the malignant transformation of
plexiform neuroï¬bromas in MPNSTs from NF1 patients.

368

Clin Cancer Res; 20(2) January 15, 2014

Clinical Cancer Research

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Wnt Pathway Activation in NF1 Tumorigenesis

Table 4. Major deregulation of the Wnt pathway expression in plexiform neuroï¬bromas and MPNSTs

Plexiform neuroï¬bromas
Wnt canonical pathway:
FZD1, SFRP4, SFRP5, TLE2,

MPNSTs
* Upregulated genes
FZD1, FZD8, DKK1, WIF1, LEF1, MSX2,

Human tumor types with previous
described alterations in WNT pathway
components

Neuroblastoma (36), colorectal cancer (37),

and MYC

SFRP1

ID2, WISP1, BMP2, TWIST1, and SOX9

and astrocytoma (39), sarcoma (31)

* Downregulated genes
WNT2, SFRP1, DKK3, KREMEN1,

Breast carcinoma (38), Melanoma (40)

b-Catenin-independant Wnt pathway: * Wnt/calcium pathway: upregulated genes
WNT9A, CAMK2B and PRKCQ

Melanoma (42â€“44)

and TCF7

WNT5A, CAMK2B and PRKCQ
* Wnt/calcium pathway: downregulated genes
WNT9A

The genes indicated in bold were found altered both in plexiform neuroï¬bromas and in MPNSTs.
The canonical Wnt pathway is mainly involved in plexiform neuroï¬bromas and MPNSTs. Eight genes were signiï¬cantly upregulated
(WNT9A, FZD1, SFRP4, SFRP5, TLE2, MYC, CAMK2B, and PRKCQ) and one was downregulated (SFRP1) in plexiform neuroï¬bromas
(as compared with dermal neuroï¬bromas). Fourteen genes were signiï¬cantly upregulated (WT5A, FZD1, FZD8, DKK1, WIF1, LEF1,
MSX2, ID2, WISP1, BMP2, TWIST1, SOX9, CAMK2B, and PRKCQ), and 6 were downregulated (WNT2, WNT9A, SFRP1, DKK3,
KREMEN1, and TCF7) in MPNSTs.

Indeed, 20 genes were signiï¬cantly deregulated in the 16
NF1-related MPNSTs and the 7 MPNST cell lines (Fig. 1 and
Supplementary Table S4). These deregulated genes encode
molecules mainly involved in the canonical Wnt pathway
(Table 4). Among them, TWIST1 and more recently SOX9
have already been identiï¬ed as major genes involved in NF1
tumorigenesis (19, 41). By using immunohistochemical
analysis, we conï¬rmed an activation of the Wnt canonical
pathway during the malignant transformation of plexiform
neuroï¬bromas in MPNSTs from NF1 patients (Fig. 3).

Wnt pathway expression analysis in a small set of non-
NF1 (sporadic) MPNSTs also suggested an activation of the
canonical Wnt pathway, as in the NF1-related MPNSTs. Our
observation conï¬rms previous results showing no differ-
ence in whole transcriptome proï¬ling between sporadic
and NF1-related MPNSTs that both present inactivation of
the 2 NF1 alleles (42).

An activation of the noncanonical Wnt/calcium pathway
was also shown during the malignant transformation of
plexiform neuroï¬bromas in MPNSTs. Finally, our results
showed a total absence of involvement of the second
noncanonical Wnt pathway-planar cell polarity path-
wayâ€”both in plexiform neuroï¬broma genesis, as well as
in MPNSTs.

Very little is known about the link between Wnt pathway
and receptor tyrosine kinase (RTK) RAS/MAPK and PI3K/
AKT signaling pathways that are activated in NF1 tumori-
genesis via the inactivation of the neuroï¬bromin (encoded
by NF1), which functions as a negative regulator of the RAS
proteins. However, several studies with culture cells showed
that activation of various tyrosine kinases (ERBB2, MET,
and RON) can increase b-catenin signaling (43â€“45).
Moreover, STI-571 (Glivec), a tyrosine kinase inhibitor,

downregulates the b-cateninâ€“signaling activity and sup-
presses cell proliferation (46). Finally, additional studies
showed that RAS pathway activation can strongly cooperate
with Wnt signaling to drive development of several type of
carcinoma in vivo (47, 48), and that PI3K/AKT pathway can
regulate Wnt signaling in various cancers (49). Our study
emphasizes the potential cooperative link between Wnt
pathway and RAS/MAPK and PI3K/AKT signaling pathways
in NF1-associated tumorigenesis. To translate our observa-
tions into potential therapies, further studies will crucial to
know which pathway(s) are critical for this link.

We conï¬rmed the NF1/WNT pathway crosstalk at the
functional level. We showed that the silencing of the Nf1
gene stimulated Wnt pathway activation in Schwann cell
lines, as in an in vitro model. Nf1 knockdown induced (i) a
Wnt pathway luciferase reporter assay activation, and (ii) an
increased active-b-catenin/total-b-catenin ratio (Fig. 3).
Our data also suggest Schwann cellâ€“speciï¬c consequences
of NF1 knockdown as no signiï¬cant Wnt gene expression
variation was found in 3 non-Schwann cell types (HEK293,
MCF-7, and MEFs).

We observed a strong association between Wnt pathway
activation and both cancer stem cell reservoir (as judged on
the expression level of stem cell markers PROM1 and
NKX2.2) and Schwannâ€“mesenchymal transition (as judged
on the expression level of EMT markers TWIST1, SLUG, and
CDH1; Table 3). It is noteworthy that NKX2.2 and TWIST1
are major Wnt targets (http://www.stanford.edu/~rnusse/
pathways/targets.html; ref. 50). Several studies suggested
that mesenchymal stem cells could differentiate into
Schwann cellâ€“like cells in physiological conditions (32).
In consequence, activation of Wnt signaling in NF1 tumor-
igenesis could promote the dedifferentiation of the tumoral

www.aacrjournals.org

Clin Cancer Res; 20(2) January 15, 2014

369

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

Luscan et al.

Schwann cells into tumoral mesenchyme cell-like. During
the process of Schwann cellâ€“mesenchyme transition, cellâ€“
cell adhesion may be downregulated and a mesenchymal
phenotype acquired, associated with increased interaction
with the extracellular matrix and an enhanced migratory
capacity. These mesenchyme cell-like could be character-
ized by a higher ability to self-renew and to induce tumor-
igenesis, both characteristics of cancer stem cells. In this
regard, we previously showed a downexpression of several
key genes in the Schwann cell lineage (ERBB3, ITGB4, and
SOX1) as well as that the deregulation of the Hedgehog
pathway (19). Wnt, Hedgehog, and Notch pathways are the
3 major signaling pathways that regulate the proliferation of
both endogenous normal stem cells and cancer stem cells
(22). For example, Clement and colleagues suggest the
Hedgehog pathway is involved in the regulation of the
glioma cancer stem cells (51).

Finally, we assume that activation of the Wnt signaling
pathway in NF1 tumorigenesis could explain the numerous
skeletal manifestations in NF1 patients. Indeed, Wnt sig-
naling is suggested to be the major common pathway
leading to bone formation, with bone morphogenetic
proteins (BMP) as only factors capable of initiating osteo-
blastogenesis from mesenchymal progenitors. Double inac-
tivation of the NF1 gene was observed in bone dysplasia
found in NF1 (52). In this study, we showed upregulation of
BMP2 in MPNST samples. We can hypothesize that activa-
tion of Wnt pathway impaired NF1
osteoblasts differ-
entiation, and has a major role in osseous abnormalities
observed in the patients with NF1.

 / 

In conclusion, our study reveals that activation of the Wnt
signaling pathway is consistently seen in NF1 tumorigen-
esis. Full conï¬rmation of the role of this pathway in NF1
needs further in vivo (animal model) studies. Our results

References
1.

Friedman JM. Epidemiology of neuroï¬bromatosis type 1. Am J Med
Genet 1999;89:1â€“6.

2. Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, Guillot B,
et al. Unravelling the genetic basis of variable clinical expression in
neuroï¬bromatosis 1. Hum Mol Genet 2009;18:2768â€“78.

3. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neuroï¬bromas in
NF1: Schwann cell origin and role of tumor environment. Science
2002;296:920â€“2.

5.

4. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, et al.
Induction of abnormal proliferation by nonmyelinating schwann
cells triggers neuroï¬broma formation. Cancer Cell 2008;13:
117â€“28.
Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microen-
vironment contribution for NF1-associated dermal neuroï¬bromas. Cell
Stem Cell 2009;4:453â€“63.
Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Voisin MC, Wechsler
J, et al. Malignant peripheral nerve sheath tumors associated with
neuroï¬bromatosis type 1: a clinicopathologic and molecular study of
17 patients. Arch Dermatol 2001;137:908â€“13.
Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association
between benign and malignant peripheral nerve sheath tumors in NF1.
Neurology 2005;65:205â€“11.

7.

6.

8. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM,
Yandell DW, et al. Chromosome 17p deletions and p53 gene mutations
associated with the formation of malignant neuroï¬brosarcomas in von

also suggest that Wnt inhibitors may represent a new
therapeutic strategy for NF1.

Disclosure of Potential Conï¬‚icts of Interest

No potential conï¬‚icts of interest were disclosed.

Authors' Contributions
Conception and design: M. Hivelin, M. Vidaud, I. Bieche, C. Massaad,
E. Pasmant
Development of methodology: A. Luscan, B. Parfait, I. Bieche
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): A. Luscan, G. Shackleford, N. Ortonne, F. Lalle-
mand, K. Leroy, V. Dumaine, M. Hivelin, D. Borderie, L. Valeyrie-Allanore,
F. Larousserie, B. Terris, L. Lantieri, P. Wolkenstein, I. Bieche
Analysis and interpretation of data (e.g., statistical analysis, biosta-
tistics, computational analysis): A. Luscan, G. Shackleford, J. Masliah-
Planchon, N. Ortonne, F. Lallemand, B. Parfait, I. Bieche, C. Massaad
Writing, review, and/or revision of the manuscript: A. Luscan,
N. Ortonne, M. Hivelin, L. Valeyrie-Allanore, P. Wolkenstein, B. Parfait,
I. Bieche, C. Massaad, E. Pasmant
Administrative, technical, or material support (i.e., reporting or orga-
nizing data, constructing databases): A. Luscan, I. Laurendeau, J. Varin,
T. De Raedt, D. Vidaud, I. Bieche, E. Pasmant
Study supervision: M. Vidaud, I. Bieche, E. Pasmant

Acknowledgments

Sporadic MPNST samples were provided by CRB-PATHOLOGIE-
COCHIN from service dâ€™anatomie et cytologie pathologiques de lâ€™h^opital
Cochin.

Grant Support

This work was supported by Association pour la Recherche sur le Cancer,
Association Neuroï¬bromatoses et Recklinghausen, Ligue FranÂ¸caise Contre
les Neuroï¬bromatoses, and Ministere de lâ€™Enseignement Superieur et de la
Recherche.

The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.

Received March 22, 2013; revised September 27, 2013; accepted October

20, 2013; published OnlineFirst November 11, 2013.

Recklinghausen neuroï¬bromatosis. Proc Natl Acad Sci U S A 1990;87:
5435â€“9.

9. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM.
Expression of p27(kip) and other cell cycle regulators in malignant
peripheral nerve sheath tumors and neuroï¬bromas: the emerging role
of p27(kip) in malignant transformation of neuroï¬bromas. Am J Pathol
1999;155:1885â€“91.

10. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg
AE, Louis DN. Malignant transformation of neuroï¬bromas in neuroï¬-
bromatosis 1 is associated with CDKN2A/p16 inactivation. Am
J Pathol 1999;155:1879â€“84.

11. DeClue JE, Heffelï¬nger S, Benvenuto G, Ling B, Li S, Rui W, et al.
Epidermal growth factor receptor expression in neuroï¬bromatosis
type 1-related tumors and NF1 animal models. J Clin Invest 2000;105:
1233â€“41.

12. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A,
et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and
neuroï¬bromatosis type 1-related malignant peripheral nerve sheath
tumors. Clin Cancer Res 2003;9:4132â€“8.

13. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med

2006;12:296â€“300.

14. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature

2005;434:843â€“50.

15. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal

transitions in development and disease. Cell 2009;139:871â€“90.

370

Clin Cancer Res; 20(2) January 15, 2014

Clinical Cancer Research

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

16. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim
M, et al. The loss of Nf1 transiently promotes self-renewal but not
tumorigenesis by neural crest stem cells. Cancer Cell 2008;13:
129â€“40.

17. Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, et al. Nf1
mutation expands an EGFR-dependent peripheral nerve progenitor
that confers neuroï¬broma tumorigenic potential. Cell Stem Cell
2008;3:658â€“69.

18. Levy P, Vidaud D, Leroy K, Laurendeau I, Wechsler J, Bolasco G, et al.
Molecular proï¬ling of malignant peripheral nerve sheath tumors asso-
ciated with neuroï¬bromatosis type 1, based on large-scale real-time
RT-PCR. Mol Cancer 2004;3:20.

19. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG,
et al. Large-scale molecular comparison of human schwann cells to
malignant peripheral nerve sheath tumor cell lines and tissues. Cancer
Res 2006;66:2584â€“91.

20. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat

Rev Mol Cell Biol 2009;10:468â€“77.

21. Klaus A, Birchmeier W. Wnt signalling and its impact on development

and cancer. Nat Rev Cancer 2008;8:387â€“98.

22. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by
inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol
2011;8:97â€“106.

23. Avellana-Adalid V, Bachelin C, Lachapelle F, Escriou C, Ratzkin B,
Baron-Van Evercooren A. In vitro and in vivo behaviour of NDF-
expanded monkey Schwann cells. Eur J Neurosci 1998;10:291â€“300.
24. Bachelin C, Lachapelle F, Girard C, Moissonnier P, Serguera-Lagache
C, Mallet J, et al. Efï¬cient myelin repair in the macaque spinal cord by
autologous grafts of Schwann cells. Brain 2005;128:540â€“9.

25. Rosenbaum T, Rosenbaum C, Winner U, Mâ‚¬uller HW, Lenard HG,
Hanemann CO. Long-term culture and characterization of human
neuroï¬broma-derived Schwann cells. J Neurosci Res 2000;61:
524â€“32.

26. Royer B, Varadaradjalou S, Saas P, Gabiot AC, Kantelip B, Feger F,
et al. Autocrine regulation of cord blood-derived human mast cell
activation by IL-10. J Allergy Clin Immunol 2001;108:80â€“6.

27. Boutry JM, Hauw JJ, Gansmuller A, Di-Bert N, Pouchelet M, Baron-Van
Evercooren A. Establishment and characterization of a mouse
Schwann cell
line which produces myelin in vivo. J Neurosci Res
1992;32:15â€“26.

28. Pasmant E, Masliah-Planchon J, Levy P, Laurendeau I, Ortonne N,
Parfait B, et al. Identiï¬cation of genes potentially involved in the
increased risk of malignancy in NF1-microdeleted patients. Mol Med
2011;17:79â€“87.

29. Pasmant E, Ortonne N, Rittie L, Laurendeau I, Levy P, Lazar V, et al.
Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1,
and CCN5/WISP2 in neuroï¬bromatosis type 1 tumorigenesis. J Neu-
ropathol Exp Neurol 2010;69:60â€“9.

30. Massaad C, Garlatti M, Wilson EM, Cadepond F, Barouki R. A natural
sequence consisting of overlapping glucocorticoid-responsive ele-
ments mediates glucocorticoid, but not androgen, regulation of gene
expression. Biochem J 2000;1:123â€“9.

31. Behrens J, Lustig B. The Wnt connection to tumorigenesis. Int J Dev

Biol 2004;48:477â€“87.

32. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA,
et al. Derivation of sarcomas from mesenchymal stem cells via inac-
tivation of the Wnt pathway. J Clin Invest 2007;117:3248â€“57.

33. Brohlin M, Mahay D, Novikov LN, Terenghi G, Wiberg M, Shawcross
SG, et al. Characterisation of human mesenchymal stem cells follow-
ing differentiation into Schwann cell-like cells. Neurosci Res 2009;64:
41â€“9.

34. Tawk M, Makoukji J, Belle M, Fonte C, Trousson A, Hawkins T, et al.
Wnt/b-catenin signaling is an essential and direct driver of myelin gene
expression and myelinogenesis. J Neurosci 2011;31:3729â€“42.

Wnt Pathway Activation in NF1 Tumorigenesis

35. Makoukji J, Belle M, Meffre D, Stassart R, Grenier J, Shackleford G,
et al. Lithium enhances remyelination of peripheral nerves. Proc Natl
Acad Sci U S A 2012;109:3973â€“8.

36. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, et al.
The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma
through activation of the Wnt/b-catenin pathway. Oncogene 2009;28:
2245â€“56.

37. Tang D, Liu J, Wang DR, Yu HF, Li YK, Zhang JQ. Diagnostic and
prognostic value of the methylation status of secreted frizzled-related
protein 2 in colorectal cancer. Clin Invest Med 2011;34:E88â€“95.

38. Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. c-Myc transforms
human mammary epithelial cells through repression of the Wnt inhi-
bitors DKK1 and SFRP1. Mol Cell Biol 2007;27:5135â€“46.

39. Rorive S, Maris C, Debeir O, Sandras F, Vidaud M, Bieche I, et al.
Exploring the distinctive biological characteristics of pilocytic and low-
grade diffuse astrocytomas using microarray gene expression proï¬les.
J Neuropathol Exp Neurol 2006;65:794â€“807.

40. Kuphal S, Lodermeyer S, Bataille F, Schuierer M, Hoang BH, Bosserh-
off AK. Expression of Dickkopf genes is strongly reduced in malignant
melanoma. Oncogene 2006;25:5027â€“36.

41. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, et al.
Integrative genomic analyses of neuroï¬bromatosis tumours identify
SOX9 as a biomarker and survival gene. EMBO Mol Med 2009;1:
236â€“48.

42. Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al.
Prognostic signiï¬cance of AKT/mTOR and MAPK pathways and
antitumor effect of mTOR inhibitor in NF1-related and sporadic malig-
nant peripheral nerve sheath tumors. Clin Cancer Res 2013;19:
450â€“61.

43. Dissanayake SK, Olkhanud PB, O'Connell MP, Carter A, French AD,
Camilli TC, et al. Wnt5A regulates expression of tumor-associated
antigens in melanoma via changes in signal transducers and activators
of transcription 3 phosphorylation. Cancer Res 2008;68:10205â€“14.

44. Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B,
Leonard EJ. Oncogenic mutants of RON and MET receptor tyrosine
kinases cause activation of the b-catenin pathway. Mol Cell Biol
2001;21:5857â€“68.

45. Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros
A, et al. Geldanamycin abrogates ErbB2 association with proteasome-
resistant b-catenin in melanoma cells, increases b-catenin-E-cadherin
association, and decreases b-catenin-sensitive transcription. Cancer
Res 2001;61:1671â€“7.

46. Zhou L, An N, Haydon RC, Zhou Q, Cheng H, Peng Y, et al. Tyrosine
kinase inhibitor STI-571/Gleevec down-regulates the b-catenin sig-
naling activity. Cancer Lett 2003;193:161â€“70.

47. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai
K, et al. A two-step model for colon adenoma initiation and progression
caused by APC loss. Cell 2009;137:623â€“34.

48. Pearson HB, Phesse TJ, Clarke AR. K-ras and Wnt signaling synergize
to accelerate prostate tumorigenesis in the mouse. Cancer Res
2009;69:94â€“101.

49. Nteliopoulos G, Marley SB, Gordon MY. Inï¬‚uence of PI-3K/Akt path-
way on Wnt signalling in regulating myeloid progenitor cell prolifera-
tion. Evidence for a role of autocrine/paracrine Wnt regulation. Br J
Haematol 2009;146:637â€“51.

50. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in
response to Wnt1 and inhibits mouse mammary cell differentiation.
Cancer Res 2003;63:1906â€“13.

51. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A.
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer
stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17:165â€“72.
52. Stevenson DA, Zhou H, Ashraï¬ S, Messiaen LM, Carey JC, D'Astous
JL, et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum
Genet 2006;79:143â€“8.

www.aacrjournals.org

Clin Cancer Res; 20(2) January 15, 2014

371

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

Published OnlineFirst November 11, 2013; DOI: 10.1158/1078-0432.CCR-13-0780 

The Activation of the WNT Signaling Pathway Is a Hallmark in
Neurofibromatosis Type 1 Tumorigenesis
Â  
Armelle Luscan, Ghjuvan'Ghjacumu Shackleford, Julien Masliah-Planchon, et al. 
Â  
Clin Cancer ResÂ 

2014;20:358-371. Published OnlineFirst November 11, 2013.

Â  
Â  
Â  
Â  

Â  
Â  

Updated version
Â  
Supplementary
Material
Â  

10.1158/1078-0432.CCR-13-0780
 

Access the most recent version of this article at:
doi:
Â  
Access the most recent supplemental material at:
 
http://clincancerres.aacrjournals.org/content/suppl/2013/11/11/1078-0432.CCR-13-0780.DC1.html
Â  

Cited Articles
Â  
Citing articles
Â  

This article cites by 52 articles, 16 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/2/358.full.html#ref-list-1
 
Â  
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/20/2/358.full.html#related-urls
 
Â  

E-mail alerts
Â  
Reprints and 
Subscriptions
Â  
Permissions
Â  

Sign up to receive free email-alerts

 related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
pubs@aacr.org
.
Â  
To request permission to re-use all or part of this article, contact the AACR Publications Department at
.
permissions@aacr.org
Â  

Downloaded from 

clincancerres.aacrjournals.org 

on May 27, 2015. Â© 2014 American Association for Cancer Research. 

